In contrast, saliva and plasma responses against IgA1, total IgG as well as FcγR3a after COVID‐19 recovered individuals received their second Vaxzevria dose (1 × prior COVID‐19 infection + 2 × Vaxzevria) did not rise to the levels seen 2 weeks after the first dose (Figure 1c, d; Supplementary figure 2b, d). The gene discussed is FCGR3A; the disease is COVID-19.